DS
ALLO icon

David Shaw’s Allogene Therapeutics ALLO Stock Holding History

David Shaw’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.8M Buy
4,710,735
+1,946,959
+70% +$4.28M ﹤0.01% 1828
2026
Q1 		$6.74M Buy
2,763,776
+1,480,805
+115% +$2.97M ﹤0.01% 1959
2025
Q4 		$1.76M Buy
1,282,971
+819,073
+177% +$1.08M ﹤0.01% 3151
2025
Q3 		$575K Buy
+463,898
New +$553K ﹤0.01% 3795
2025
Q1 		– Sell
-54,517
Closed -$116K – 4223
2024
Q4 		$116K Sell
54,517
-35,808
-40% -$88.3K ﹤0.01% 4155
2024
Q3 		$253K Sell
90,325
-149,930
-62% -$400K ﹤0.01% 4061
2024
Q2 		$560K Buy
240,255
+44,477
+23% +$131K ﹤0.01% 3558
2024
Q1 		$875K Buy
195,778
+120,138
+159% +$501K ﹤0.01% 3177
2023
Q4 		$243K Sell
75,640
-48,598
-39% -$138K ﹤0.01% 3819
2023
Q3 		$394K Sell
124,238
-151,610
-55% -$664K ﹤0.01% 3516
2023
Q2 		$1.37M Sell
275,848
-236,828
-46% -$1.28M ﹤0.01% 2899
2023
Q1 		$2.53M Sell
512,676
-147,511
-22% -$946K ﹤0.01% 2506
2022
Q4 		$4.15M Buy
660,187
+220,492
+50% +$2.04M ﹤0.01% 2266
2022
Q3 		$4.75M Buy
439,695
+156,004
+55% +$2.12M 0.01% 2155
2022
Q2 		$3.23M Sell
283,691
-701,412
-71% -$6.23M ﹤0.01% 2632
2022
Q1 		$8.97M Buy
985,103
+455,288
+86% +$4.74M 0.01% 1697
2021
Q4 		$7.91M Buy
529,815
+507,107
+2,233% +$8.95M 0.01% 1902
2021
Q3 		$584K Sell
22,708
-179,555
-89% -$4.26M ﹤0.01% 3993
2021
Q2 		$5.28M Buy
+202,263
New +$5.77M ﹤0.01% 1982
2020
Q4 		– Sell
-6,459
Closed -$244K – 3887
2020
Q3 		$244K Buy
+6,459
New +$244K ﹤0.01% 3543
2020
Q1 		– Sell
-125,030
Closed -$3.25M – 3893
2019
Q4 		$3.25M Buy
+125,030
New +$3.44M ﹤0.01% 2086

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

David Shaw's ALLO Position: Q2 2026 in Review

David Shaw increased its Allogene Therapeutics (ALLO) stake by 70% in Q2 2026, buying an estimated $4.28M and bringing the position to 4,710,735 shares worth $9.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1828.

David Shaw first reported a position in ALLO in Q4 2019 and has held it in 21 quarters since. 208 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • David Shaw held 4,710,735 shares of Allogene Therapeutics worth $9.8M as of Q2 2026.
  • David Shaw bought 1,946,959 Allogene Therapeutics shares in Q2 2026, an estimated $4.28M.
  • Allogene Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #1828 holding.
  • David Shaw first reported a position in Allogene Therapeutics in Q4 2019 and has held it in 21 quarters since.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.